仰卧位血浆去甲肾上腺素水平预测神经源性直立性低血压患者对屈昔多巴的升压反应
该观察性研究纳入20例神经源性直立性低血压患者,分析仰卧位血浆去甲肾上腺素水平与屈昔多巴升压反应的关系。结果显示较低的仰卧位血浆去甲肾上腺素水平与更大的升压效应相关,且该水平可较准确识别对标准剂量屈昔多巴有反应的患者。
要点
- 仰卧位血浆去甲肾上腺素水平较低者,屈昔多巴给药1小时后的升压效应更大。
- 对屈昔多巴无升压反应者仰卧位血浆去甲肾上腺素水平较高(382±100 vs 115±20 pg/mL,p=0.0014)。
- 仰卧位血浆去甲肾上腺素<219.5 pg/mL预测升压反应的敏感度为83%、特异度为93%。
核心结论
- 在神经源性直立性低血压患者中,较低的仰卧位静息血浆去甲肾上腺素水平与屈昔多巴更大的升压效应相关,该发现有助于识别最可能对标准剂量屈昔多巴有反应的患者。
研究设计与样本
- 观察性研究,纳入20例神经源性直立性低血压患者,病因包括帕金森病、单纯自主神经衰竭、多系统萎缩或自身免疫性自主神经病。
- 所有患者接受标准化自主神经功能检测,包括经留置导管在静息仰卧位时测定静脉血浆儿茶酚胺水平。
- 随后进行屈昔多巴滴定,连续数日以100 mg递增,直至症状缓解、出现副作用或达到最大剂量600 mg。
- 无反应定义为屈昔多巴给药后1小时、站立3分钟时收缩压升高<10 mm Hg。
- 采用非线性回归模型确定血压反应与血浆去甲肾上腺素水平的关系。
主要发现
- 患者仰卧位血浆去甲肾上腺素水平范围为44至850 pg/mL。
- 较低的仰卧位血浆去甲肾上腺素水平与给药1小时后更大的升压效应相关(R²=0.49),并与更高的站立位血压相关(R²=0.45)。
- 对屈昔多巴无升压反应者仰卧位血浆去甲肾上腺素水平较高(382±100 vs 115±20 pg/mL,p=0.0014)。
- 仰卧位血浆去甲肾上腺素<219.5 pg/mL预测升压反应的敏感度为83%、特异度为93%(曲线下面积=0.95,p=0.0023)。
关键数值与推荐
- 无反应定义:屈昔多巴给药后1小时、站立3分钟时收缩压升高<10 mm Hg。
- 屈昔多巴滴定方案:连续数日以100 mg递增,直至症状缓解、出现副作用或达到最大剂量600 mg。
- 仰卧位血浆去甲肾上腺素<219.5 pg/mL预测升压反应:敏感度83%、特异度93%、曲线下面积=0.95(p=0.0023)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test whether the plasma levels of norepinephrine (NE) in patients with neurogenic orthostatic hypotension (nOH) predict their pressor response to droxidopa. METHODS: This was an observational study, which included patients with nOH. All patients had standardized autonomic function testing including determination of venous plasma catecholamine levels drawn through an indwelling catheter while resting supine. This was followed by a droxidopa titration with 100 mg increments in successive days until relief of symptoms, side effects, or the maximum dose of 600 mg was reached. No response was defined as an increase of <10 mm Hg in systolic blood pressure (BP) after 3-minute standing 1 hour after droxidopa administration. Nonlinear regression models were used to determine the relationship between BP response and plasma NE levels. RESULTS: We studied 20 patients with nOH due to Parkinson disease, pure autonomic failure, multiple system atrophy, or autoimmune autonomic neuropathies. Their supine plasma NE levels ranged from 44 to 850 pg/mL. Lower supine plasma NE levels were associated with greater pressor effect 1 hour after dose (R2 = 0.49) and higher standing BP (R2 = 0.45). Patients with no pressor response to droxidopa had higher NE levels (382 ± 100 vs 115 ± 20 pg/mL, p = 0.0014). A supine NE level of <219.5 pg/mL had 83% sensitivity and 93% specificity to predict a pressor response (area under the curve = 0.95, p = 0.0023). CONCLUSIONS: In patients with nOH, lower supine resting plasma NE levels are associated with a greater pressor effect of droxidopa treatment. This finding should help identify patients with nOH most likely to respond to standard doses of droxidopa. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower supine plasma NE levels accurately identify patients with nOH more likely to have a greater pressor effect from droxidopa.
引用
- Palma JA, Norcliffe-Kaufmann L, Martinez J, et al. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018. PMID: 30232253. doi:10.1212/WNL.0000000000006369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。